EMA Withdrawn: Zynrelef (bupivacaine;meloxicam) — Heron Therapeutics, B.V.

View source ↗

Summary

The EMA has withdrawn Zynrelef, a bupivacaine/meloxicam combination, from the market for postoperative pain management.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postoperative Pain

Drugs mentioned

• ZYNRELEF (BUPIVACAINE AND MELOXICAM)

Snippet

Status: Withdrawn. Therapeutic area: Pain, Postoperative. MAH: Heron Therapeutics, B.V.. Decision date: 05/10/2023